During the pathogenesis of Parkinson’s disease (PD), α-synuclein pathology may originate in peripheral organs and spread to the CNS. Using human tissue samples and multiple approaches in mouse ...

Clinical diagnosis of Parkinson's disease (PD) could be performed in ... and serotoninergic systems has been implicated in the pathogenesis of depression in PD. They have been associated with ...

The Aligning Science Across Parkinson’s (ASAP) initiative opened applications for members of the research community to apply to join the Collaborative Research Network (CRN) 2025 Scientific Track. The ...

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

During the past decade, Parkinson disease (PD) has evolved from a textbook ... markedly improved our conception of its etiology and pathophysiology; however, the identification of different ...

Among participants who did not have Parkinson’s, the test showed the absence of the disease 96% of the time ... substantial way to understanding the pathogenesis of Parkinson’s, and the ...

Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...

The article "Alleviating Stress in Parkinson's Disease: Symptomatic Treatment ... and stress-alleviation on clinical symptoms and the pathophysiology in PD. "In people with PD, stress is thought ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...